Skip to main content
Premium Trial:

Request an Annual Quote

Xceleron and Servier to Accelerate Drug Development Using Microdosing

NEW YORK, Dec. 8, (GenomeWeb News) - Under a collaborative agreement, XCeleron will provide Servier accelerator mass spectrometry services to study candidate drugs in humans, Xceleron said yesterday.


Servier will accelerate drug development by testing candidate drugs in phase 0 microdose studies instead of waiting for conventional phase 1 studies.


The 12-month rolling agreement allows the pharmaceutical company to include early human studies as part of its drug candidate selection process, Xceleron said.


Financial details were not disclosed.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.